Literature DB >> 22536933

Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.

Suzanne F Jones1, Jeffrey R Infante, David R Spigel, Nancy W Peacock, Dana S Thompson, F Anthony Greco, William McCulloch, Howard A Burris.   

Abstract

Romidepsin is a potent histone deacetylase inhibitor; preclinical studies showed potential synergy with the nucleoside analog gemcitabine. This phase 1 trial was conducted to determine the maximum tolerated dose for two schedules of romidepsin plus gemcitabine in patients with advanced solid tumors in which gemcitabine had previously demonstrated clinical activity. The recommended phase 2 dose was 12 mg/m(2) romidepsin plus 800 mg/m(2) gemcitabine on days 1 and 15 every 28 days. Results suggest additive hematologic toxicities of romidepsin plus gemcitabine, but the level of antitumor activity observed warrants more formal trials of this combination to further assess safety and efficacy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22536933     DOI： 10.3109/07357907.2012.675382

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  13 in total

1.  Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

Authors:  David E Gerber; David A Boothman; Farjana J Fattah; Ying Dong; Hong Zhu; Rachel A Skelton; Laurin L Priddy; Peggy Vo; Jonathan E Dowell; Venetia Sarode; Richard Leff; Claudia Meek; Yang Xie; Joan H Schiller
Journal:  Lung Cancer       Date:  2015-10-09       Impact factor: 5.705

Review 2.  Targeting Histone Deacetylases in Diseases: Where Are We?

Authors:  Rosaria Benedetti; Mariarosaria Conte; Lucia Altucci
Journal:  Antioxid Redox Signal       Date:  2014-03-06       Impact factor: 8.401

Review 3.  Developing effective combination therapy for pancreatic cancer: An overview.

Authors:  Aubrey L Miller; Patrick L Garcia; Karina J Yoon
Journal:  Pharmacol Res       Date:  2020-03-02       Impact factor: 7.658

Review 4.  Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.

Authors:  Dietrich A Ruess; Kivanc Görgülü; Sonja M Wörmann; Hana Algül
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 4.271

Review 5.  Current Status of Immunotherapies for Treating Pancreatic Cancer.

Authors:  Annie A Wu; Elizabeth Jaffee; Valerie Lee
Journal:  Curr Oncol Rep       Date:  2019-05-17       Impact factor: 5.945

Review 6.  Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

Authors:  Madhusoodanan Mottamal; Shilong Zheng; Tien L Huang; Guangdi Wang
Journal:  Molecules       Date:  2015-03-02       Impact factor: 4.411

Review 7.  Combination therapy in combating cancer.

Authors:  Reza Bayat Mokhtari; Tina S Homayouni; Narges Baluch; Evgeniya Morgatskaya; Sushil Kumar; Bikul Das; Herman Yeger
Journal:  Oncotarget       Date:  2017-06-06

8.  A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.

Authors:  Pawat Pattarawat; Jessica T Hunt; Jacob Poloway; Collin J Archibald; Hwa-Chain Robert Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-27       Impact factor: 3.288

9.  A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.

Authors:  Cinzia Pellegrini; Anna Dodero; Annalisa Chiappella; Federico Monaco; Debora Degl'Innocenti; Flavia Salvi; Umberto Vitolo; Lisa Argnani; Paolo Corradini; Pier Luigi Zinzani
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

Review 10.  Use of class I histone deacetylase inhibitor romidepsin in combination regimens.

Authors:  Adam Petrich; Chadi Nabhan
Journal:  Leuk Lymphoma       Date:  2016-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.